Can surgical axillary staging be safely omitted in early-stage invasive lobular carcinoma? Results from a large multicenter retrospective study
In brief
Clinically node-negative lobular cancer still had extensive nodal disease in 2.5%
In this retrospective study of 1,886 patients with early-stage invasive lobular breast cancer, 17.6% had cancer in their lymph nodes and 2.5% had more extensive nodal disease. Skipping sentinel node biopsy could therefore leave some patients understaged; the authors suggest limiting omission to selected patients with small, unifocal, hormone receptor-positive tumors and no other risk features.
- Journal
- Breast (Edinburgh, Scotland) (Q1)
- Published
- 5 November 2026
- Study design
- Retrospective cohort
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Massimo Ferrucci, Francesco Milardi, Daniele Passeri, Veronica Casotto, Carla Cedolini, Serena Scomersi, et al.
- PMID
- 43044490
- DOI
- 10.1016/j.breast.2026.104952
Why clinicians should know about it
- Picked for Surgical Oncology (paper of the day, 19 November 2026): Axillary staging omission in early lobular carcinoma
Abstract
BACKGROUND: The SOUND and INSEMA trials demonstrated that, in selected patients with clinically node-negative (cN0) early-stage breast cancer, omission of sentinel lymph node biopsy (SLNB) does not compromise survival outcomes. However, patients with invasive lobular carcinoma (ILC) were underrepresented. We evaluated axillary nodal burden in consecutive patients with cT1-2N0 ILC, to assess the feasibility of omitting SLNB in this population. METHODS: This multicenter retrospective study included patients with cT1-2 cN0 ILC, who underwent upfront surgery between 2012 and 2025 across three high-volume Italian breast units. All patients underwent preoperative axillary ultrasound, with needle sampling performed for suspicious lymph nodes. Univariable and multivariable logistic regression analyses identified factors associated with pN2-3 nodal disease. RESULTS: A total of 1886 patients were included (median age, 65 years). Median radiologic tumor size was 16 mm (IQR 11-23). Most patients underwent SLNB (86.7%), the remaining had axillary lymph node dissection. Overall, 332/1886 patients (17.6%) were node-positive, of whom 48/1886 (2.5%) had pN2-3 disease. On univariable analyses, palpable tumors (OR 3.59; p < 0.001), ultrasound-suspicious axillary nodes (OR 8.19; p < 0.001), T2 tumors (OR 2.96; p = 0.002), multicentric distribution (OR 4.50; p < 0.001), high tumor grade (OR 2.15; p = 0.03), lymphovascular invasion (LVI) (OR 3.25; p = 0.001) and HER2-positivity (OR 3.81; p = 0.022) were associated with pN2-3 disease. On multivariable analysis, ultrasound-suspicious axillary nodes (OR 5.76; p = 0.002), T2 tumors measuring 41-50 mm (OR 14.18, p = 0.003), presence of LVI (OR 3.65; p = 0.006), multicentric distribution (OR 5.19; p < 0.001), and HER2-positivity (OR 3.86; p = 0.041) remained independently associated with pN2-3 disease. CONCLUSIONS: In this large real-world cohort of patients with cT1-2 cN0 ILC, the prevalence of pN2-3 disease was 2.5%. Omission of SLNB in this population may result in understaging, potentially affecting adjuvant treatment decisions. This approach may be best reserved for selected cT1 cN0 patients with hormone receptor-positive, HER2-negative, unifocal tumors without LVI or suspicious axillary ultrasound.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.